Search

Your search keyword '"Laskin, J."' showing total 936 results

Search Constraints

Start Over You searched for: Author "Laskin, J." Remove constraint Author: "Laskin, J."
936 results on '"Laskin, J."'

Search Results

2. Whole-genome and transcriptome analysis enhances precision cancer treatment options

3. Molecular composition of particulate matter emissions from dung and brushwood burning household cookstoves in Haryana, India

4. Effect of relative humidity on the composition of secondary organic aerosol from the oxidation of toluene

5. Molecular Diversity of Sea Spray Aerosol Particles: Impact of Ocean Biology on Particle Composition and Hygroscopicity

7. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

8. A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies

9. Complex refractive indices in the near-ultraviolet spectral region of biogenic secondary organic aerosol aged with ammonia

10. Effect of humidity on the composition of isoprene photooxidation secondary organic aerosol

13. Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study

16. LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

22. EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer

23. EP08.02-108 Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study

30. OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer

37. P89.03 Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System

40. 1195P The value of detecting resistance through liquid biopsy

42. Fusions NRG1 et adénocarcinomes pulmonaires : l’afatinib comme traitement potentiel

43. Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

50. Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer

Catalog

Books, media, physical & digital resources